Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 73

1.

Tissue microarray constructs to predict a response to chemoradiation in rectal cancer.

Huerta S, Hrom J, Gao X, Saha D, Anthony T, Reinhart H, Kapur P.

Dig Liver Dis. 2010 Oct;42(10):679-84. doi: 10.1016/j.dld.2010.02.003. Epub 2010 Mar 15.

PMID:
20227932
2.

Tumor response to neoadjuvant chemoradiation in rectal cancer: predictor for surgical morbidity?

Horisberger K, Hofheinz RD, Palma P, Volkert AK, Rothenhoefer S, Wenz F, Hochhaus A, Post S, Willeke F.

Int J Colorectal Dis. 2008 Mar;23(3):257-64. Epub 2007 Dec 11.

PMID:
18071720
3.

Chemoradiation for rectal cancer: rationale, approaches, and controversies.

Minsky BD.

Surg Oncol Clin N Am. 2010 Oct;19(4):803-18. doi: 10.1016/j.soc.2010.06.001. Review.

PMID:
20883955
4.

Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study.

Valentini V, Morganti AG, Gambacorta MA, Mohiuddin M, Doglietto GB, Coco C, De Paoli A, Rossi C, Di Russo A, Valvo F, Bolzicco G, Dalla Palma M; Study Group for Therapies of Rectal Malignancies (STORM)..

Int J Radiat Oncol Biol Phys. 2006 Mar 15;64(4):1129-39. Epub 2006 Jan 18.

PMID:
16414206
5.

p53 protein overexpression and response to induction chemoradiation therapy in patients with locally advanced rectal adenocarcinoma.

Luna-Perez P, Arriola EL, Cuadra Y, Alvarado I, Quintero A.

Ann Surg Oncol. 1998 Apr-May;5(3):203-8.

PMID:
9607618
6.
7.

p53 immunohistochemical staining predicts residual disease after chemoradiation in patients with high-risk rectal cancer.

Spitz FR, Giacco GG, Hess K, Larry L, Rich TA, Janjan N, Cleary KR, Skibber JM.

Clin Cancer Res. 1997 Oct;3(10):1685-90.

8.

Magnetic resonance imaging accuracy in assessing tumour down-staging following chemoradiation in rectal cancer.

Suppiah A, Hunter IA, Cowley J, Garimella V, Cast J, Hartley JE, Monson JR.

Colorectal Dis. 2009 Mar;11(3):249-53. doi: 10.1111/j.1463-1318.2008.01593.x. Epub 2008 May 29.

PMID:
18513192
9.

Prognostic value of pathologic complete response after neoadjuvant therapy in locally advanced rectal cancer: long-term analysis of 566 ypCR patients.

Capirci C, Valentini V, Cionini L, De Paoli A, Rodel C, Glynne-Jones R, Coco C, Romano M, Mantello G, Palazzi S, Mattia FO, Friso ML, Genovesi D, Vidali C, Gambacorta MA, Buffoli A, Lupattelli M, Favretto MS, La Torre G.

Int J Radiat Oncol Biol Phys. 2008 Sep 1;72(1):99-107. doi: 10.1016/j.ijrobp.2007.12.019. Epub 2008 Apr 11.

PMID:
18407433
10.

Intraoperative presacral electron boost following preoperative chemoradiation in T3-4Nx rectal cancer: initial local effects and clinical outcome analysis.

Calvo FA, Gómez-Espí M, Díaz-González JA, Alvarado A, Cantalapiedra R, Marcos P, Matute R, Martínez NE, Lozano MA, Herranz R.

Radiother Oncol. 2002 Feb;62(2):201-6.

PMID:
11937247
11.

Prognostic implications of response to preoperative infusional chemoradiation in locally advanced rectal cancer.

Janjan NA, Abbruzzese J, Pazdur R, Khoo VS, Cleary K, Dubrow R, Ajani J, Rich TA, Goswitz MS, Evetts PA, Allen PK, Lynch PM, Skibber JM.

Radiother Oncol. 1999 May;51(2):153-60.

PMID:
10435807
12.

Different prognostic effect of postoperative chemoradiation therapy on diploid and nondiploid high-risk rectal cancers.

Tang R, Ho YS, Chen HH, See LC, Wang JY.

Dis Colon Rectum. 1998 Dec;41(12):1494-9.

PMID:
9860328
13.

Addition of weekly oxaliplatin to standard preoperative chemoradiation for locally advanced rectal cancer.

Aschele C, Lonardi S.

J Clin Oncol. 2007 Feb 10;25(5):602-3; author reply 603. No abstract available.

PMID:
17290071
14.

Complete pathologic response following preoperative chemoradiation therapy for middle to lower rectal cancer is not a prognostic factor for a better outcome.

Pucciarelli S, Toppan P, Friso ML, Russo V, Pasetto L, Urso E, Marino F, Ambrosi A, Lise M.

Dis Colon Rectum. 2004 Nov;47(11):1798-807.

PMID:
15622571
15.

Lymph node micrometastasis in stage II distal rectal cancer following neoadjuvant chemoradiation therapy.

Perez RO, Habr-Gama A, Nishida Arazawa ST, Rawet V, Coelho Siqueira SA, Kiss DR, Gama-Rodrigues JJ.

Int J Colorectal Dis. 2005 Sep;20(5):434-9. Epub 2005 Mar 10.

PMID:
15759124
16.

Just how useful an endpoint is complete pathological response after neoadjuvant chemoradiation in rectal cancer?

Glynne-Jones R, Anyamene N.

Int J Radiat Oncol Biol Phys. 2006 Oct 1;66(2):319-20. No abstract available.

PMID:
16965984
17.

Fewer than 12 lymph nodes can be expected in a surgical specimen after high-dose chemoradiation therapy for rectal cancer.

Marks JH, Valsdottir EB, Rather AA, Nweze IC, Newman DA, Chernick MR.

Dis Colon Rectum. 2010 Jul;53(7):1023-9. doi: 10.1007/DCR.0b013e3181dadeb4.

PMID:
20551754
18.

Interpretation of magnetic resonance imaging for locally advanced rectal carcinoma after preoperative chemoradiation therapy.

Kuo LJ, Chern MC, Tsou MH, Liu MC, Jian JJ, Chen CM, Chung YL, Fang WT.

Dis Colon Rectum. 2005 Jan;48(1):23-8.

PMID:
15690653
19.

Germline polymorphisms may act as predictors of response to preoperative chemoradiation in locally advanced T3 rectal tumors.

Spindler KL, Nielsen JN, Lindebjerg J, Jakobsen A.

Dis Colon Rectum. 2007 Sep;50(9):1363-9.

PMID:
17661145
20.

Instrumental clinical restaging, pathological evaluation, and tumor regression grading: how to assess the response to neoadjuvant chemoradiotherapy for rectal cancer.

Benzoni E, Terrosu G, Intersimone D, Milan E, Chiaulon G, Bresadola V, Sacco C, Sattin E, Bresadola F, Avellini C.

Int J Colorectal Dis. 2007 Jan;22(1):7-13. Epub 2006 Mar 15.

PMID:
16538492

Supplemental Content

Support Center